Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC
Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC
Recruiting · NCT07040072 · Registry updated 2026-05-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 1 | 2026-05-04 | NCT07040072 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beijing Tongren Hospital | 60 |
| Keymed Biosciences Co.Ltd | 28 |
| Sinocelltech Ltd. | 32 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Tongren Hospital, Capital Medical University | Beijing | China | 11 |